Geode Capital Management Portfolio holdings
Geode Capital Management, founded in 2001 and based in Boston, Massachusetts, is a prominent institutional asset management firm known for its expertise in low-cost, systematic index investing. Originally established to manage internal index funds for Fidelity Investments, Geode became an independent entity while retaining a close relationship with Fidelity, focusing on passive investment strategies that track major market indices. The firm oversees hundreds of billions in assets, offering a range of mutual funds and separately managed accounts primarily for institutional clients, such as pension funds and endowments, with an emphasis on minimizing costs and maximizing efficiency. Geode’s disciplined, quantitative approach and avoidance of active management have made it a key player in the rise of index-based investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$524M |
| 2 |
Meta Platforms (Facebook)
META
|
+$458M |
| 3 |
Otis Worldwide
OTIS
|
+$345M |
| 4 |
T-Mobile US
TMUS
|
+$307M |
| 5 |
AbbVie
ABBV
|
+$280M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$878M |
| 2 |
RTN
Raytheon Company
RTN
|
+$537M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$435M |
| 4 |
Apple
AAPL
|
+$389M |
| 5 |
Accenture
ACN
|
+$216M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.72% |
| 2 | Healthcare | 14.52% |
| 3 | Financials | 12.98% |
| 4 | Consumer Discretionary | 10.98% |
| 5 | Communication Services | 9.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2526
CRISPR Therapeutics
CRSP
$5.18B
| $3.48M | ﹤0.01% |
47,399
+4,449
| +10% | +$260K |
|
2527
Purple Innovation
PRPL
$42.9M
| $3.48M | ﹤0.01% |
7,727
+1,441
| +23% | +$454K |
|
|
AKTS
2528
DELISTED
Akoustis Technologies Inc
AKTS
| $3.47M | ﹤0.01% |
418,307
-60,216
| -13% | -$465K |
|
2529
SAP
SAP
$224B
| $3.47M | ﹤0.01% |
24,749
-3,898
| -14% | -$480K |
|
|
CRON
2530
Cronos Group
CRON
$1.05B
| $3.46M | ﹤0.01% |
575,248
+104,880
| +22% | +$641K |
|
|
OPTN
2531
DELISTED
OptiNose
OPTN
| $3.46M | ﹤0.01% |
30,972
+2,300
| +8% | +$164K |
|
2532
Merchants Bancorp
MBIN
$2.56B
| $3.45M | ﹤0.01% |
279,689
+5,382
| +2% | +$56.8K |
|
|
BFYT
2533
DELISTED
Benefytt Technologies, Inc. Class A Common Stock
BFYT
| $3.45M | ﹤0.01% |
168,520
+11,525
| +7% | +$244K |
|
|
MNK
2534
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $3.44M | ﹤0.01% |
1,283,367
+21,173
| +2% | +$63.5K |
|
2535
SmartFinancial
SMBK
$912M
| $3.43M | ﹤0.01% |
212,296
+15,769
| +8% | +$230K |
|
|
SCU
2536
DELISTED
Sculptor Capital Management, Inc. Class A Common Stock
SCU
| $3.43M | ﹤0.01% |
265,420
+13,635
| +5% | +$175K |
|
2537
Greif Class B
GEF.B
$4.19B
| $3.43M | ﹤0.01% |
82,013
-217
| -0.3% | -$8.5K |
|
|
LCI
2538
DELISTED
Lannett Company, Inc.
LCI
| $3.41M | ﹤0.01% |
117,537
+933
| +0.8% | +$29K |
|
|
LDL
2539
DELISTED
Lydall, Inc.
LDL
| $3.41M | ﹤0.01% |
251,654
+8,434
| +3% | +$93.3K |
|
2540
ACNB Corp
ACNB
$667M
| $3.37M | ﹤0.01% |
128,905
+10,819
| +9% | +$268K |
|
2541
Transmedics
TMDX
$2.79B
| $3.37M | ﹤0.01% |
187,798
+43,081
| +30% | +$674K |
|
|
EIGR
2542
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $3.36M | ﹤0.01% |
11,672
+831
| +8% | +$245K |
|
2543
eGain
EGAN
$199M
| $3.36M | ﹤0.01% |
302,316
+21,692
| +8% | +$197K |
|
|
CYBE
2544
DELISTED
Cyberoptics Corp
CYBE
| $3.36M | ﹤0.01% |
104,208
+42,483
| +69% | +$1.19M |
|
|
RBNC
2545
DELISTED
Reliant Bancorp, Inc. Common Stock
RBNC
| $3.36M | ﹤0.01% |
206,049
+59,042
| +40% | +$789K |
|
2546
Lifecore Biomedical
LFCR
$164M
| $3.35M | ﹤0.01% |
421,167
+3,379
| +0.8% | +$34.9K |
|
2547
Village Super Market
VLGEA
$663M
| $3.35M | ﹤0.01% |
120,900
+7,198
| +6% | +$173K |
|
|
RUTH
2548
DELISTED
Ruth's Hospitality Group, Inc.
RUTH
| $3.35M | ﹤0.01% |
410,547
+10,134
| +3% | +$88.3K |
|
|
TUP
2549
DELISTED
Tupperware Brands Corporation
TUP
| $3.33M | ﹤0.01% |
700,502
+35,771
| +5% | +$119K |
|
|
STSA
2550
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
| $3.33M | ﹤0.01% |
115,702
+33,810
| +41% | +$783K |
|
Similar funds
Geode Capital Management's Q2 2020 Portfolio in Review
As of Q2 2020, Geode Capital Management held 4,219 positions worth $467B, up 22% from $384B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Geode Capital Management's Q2 2020 filing shows 118 new, 2,550 increased, 1,055 reduced and 119 closed positions. Its largest new stake was Otis Worldwide: 6,650,358 shares worth $377M. The largest sale was Allergan plc, an estimated $878M.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 22% a quarter earlier, followed by Healthcare and Financials.
- Geode Capital Management's largest Q2 2020 buy was Otis Worldwide: 6,650,358 shares worth $377M.
- Geode Capital Management added most to Amazon in Q2 2020, an estimated $524M increase.
- Geode Capital Management's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $435M.
- Geode Capital Management fully exited Allergan plc in Q2 2020, selling an estimated $878M.
- Geode Capital Management's ten largest holdings make up 23% of its $467B portfolio in Q2 2020.
- Geode Capital Management opened 118 new positions and closed 119 in Q2 2020.
- Geode Capital Management's portfolio value rose 22% quarter-over-quarter to $467B.
Based on Geode Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.